Monitor for filing of a plan of reorganization or disclosure statement, which the company has not yet submitted. The cash burn rate and DIP facility availability will determine how long the company can operate in Chapter 11 before needing to restructure or liquidate.
Price Chart
Executive Summary
Sangamo Therapeutics filed its Chapter 11 monthly operating report for August 2026, showing a net loss of $14.4 million for the month and cumulative losses of $29.4 million since the petition date. The company reported $430,190 in revenue, $23.2 million in cash, and total liabilities of $107.3 million against $147.9 million in assets. The company drew an additional $7 million under its DIP facility during the period and sold equipment for $2.3 million in cash plus a $250,000 credit bid against DIP obligations.
Key Facts
- Net loss of $14,449,029 for August 2026; cumulative net loss of $29,369,386 since petition date
- Revenue of $430,190 for August 2026, down from $720,000 in July 2026
- Cash balance of $23,225,696 at month-end, up from $16,906,954 beginning balance
- Total liabilities of $107,262,249 vs total assets of $147,881,705
- Prepetition unsecured debt of $78,651,484
- DIP loan payables of $24,942,000 at August 31, 2026
- Drew $7 million in additional DIP obligations during the period
- Sold equipment for $2,300,000 cash plus $250,000 credit bid against DIP obligations
- Stockholders' equity negative ($6,727,000) as of August 31, 2026
- Common stock delisted from Nasdaq, trading on OTC Pink under SGMOQ
- 73 full-time employees currently vs 74 at petition date
- No plan of reorganization or disclosure statement filed with the court
Financial Impact
Net loss of $14.4M in August, cumulative $29.4M loss since Chapter 11 filing; revenue declining month-over-month; negative equity of $6.7M; $78.7M in prepetition unsecured debt
Risk Factors
- No plan of reorganization filed yet, increasing risk of conversion to Chapter 7
- Negative stockholders' equity of $6.7 million
- Revenue declining month-over-month ($720K in July to $430K in August)
- Prepetition unsecured debt of $78.7 million may result in zero recovery for common equity
- Stock delisted from Nasdaq and trading on OTC Pink with highly speculative value
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-423054 |
| Document: d453907d8k.htm | 0001193125-26-423054 |
| Document: 0001193125-26-423054-index-headers.html | 0001193125-26-423054 |
| Document: 0001193125-26-423054-index.html | 0001193125-26-423054 |
| Document: 0001193125-26-423054.txt | 0001193125-26-423054 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $0.1100 $0.1200 | ▼ −9.09% | ▼ −9.52% | $0.1200 (−9.09%) |
Oct 6, 2026 19d ago | 25-NSE | $0.1400 $0.1400 | · 0.00% | ▼ −0.98% | $0.1200 (+14.29%) |
Aug 28, 2026 8w ago | 8-K | $0.1600 $0.1600 | · 0.00% | ▼ −0.14% | $0.1200 (+25.00%) |
Aug 12, 2026 10w ago | 8-K | $0.1700 $0.1602 | ▼ −5.76% | ▼ −3.80% | $0.1200 (−29.41%) |
Aug 12, 2026 10w ago | 8-K | $0.1700 $0.1602 | ▲ +5.76% | ▲ +3.80% | $0.1200 (+29.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers